10-Q: Blue Biofuels Q1 2026: Continued Losses Amidst R&D Investment

Blue Biofuels reports zero revenue for Q1 2026, with net losses widening due to increased R&D spending and a lack of government grant income compared to the prior year, while cash reserves dwindle.

Summary

• Blue Biofuels, Inc. reported no revenue for the first quarter ended March 31, 2026, similar to the same period in 2025.
• The company experienced a net loss of $663,801 for Q1 2026, a significant increase from the $243,833 loss in Q1 2025.
• General and administrative expenses decreased by $63,513 to $274,585 in Q1 2026, primarily due to lower consulting expenses.
• Research and development expenses increased by $34,206 to $384,913 in Q1 2026, largely driven by higher equity-based compensation.
• Cash and cash equivalents significantly decreased to $8,665 as of March 31, 2026, from $65,200 as of December 31, 2025.
• Total liabilities increased by $132,904 to $5,246,366 as of March 31, 2026, mainly due to an increase in deferred wages.
• The company raised $372,000 in financing activities during Q1 2026, primarily from a private placement and warrant exercises, compared to $100,000 in Q1 2025.
• The company continues to face substantial doubt regarding its ability to continue as a going concern due to recurring operating losses and the need for additional financing.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the widening net loss, declining cash reserves, and the continued emphasis on the going concern uncertainty, despite some positive financing activities.

Positives

• General and administrative expenses decreased by $63,513 to $274,585 in Q1 2026 compared to Q1 2025.
• The company successfully raised $372,000 in financing activities during Q1 2026, an increase from $100,000 in Q1 2025, through a private placement and warrant exercises.
• The company has secured a $1.15 million Small Business Innovation Research (SBIR) grant from the U.S. Department of Energy to further develop its patented CTS process.

Negatives

• Zero revenue generated in Q1 2026, consistent with Q1 2025.
• Net loss increased to $663,801 in Q1 2026 from $243,833 in Q1 2025.
• Cash and cash equivalents decreased significantly from $65,200 at the end of 2025 to $8,665 at the end of Q1 2026.
• Total liabilities increased to $5,246,366 as of March 31, 2026.
• Net cash used in operating activities was $418,535 in Q1 2026, a reversal from net cash provided by operating activities of $13,416 in Q1 2025, largely due to the absence of grant income.
• Substantial doubt exists regarding the company's ability to continue as a going concern.

Risks

• The company has incurred accumulated losses of $60,794,163 as of March 31, 2026, and expects to incur significant additional losses.
• The company's ability to continue as a going concern is dependent on obtaining necessary financing and generating sufficient revenues.
• There is no assurance that the company will be able to generate sufficient cash from operations, sell additional shares, or borrow additional funds.
• The inability to obtain additional cash could materially and adversely affect the company's financial position, results of operations, and ability to continue in existence.
• The company anticipates needing additional funds for G&A expenses and project financing for a commercial ethanol to SAF facility.
• There is no guarantee that the company will achieve all necessary additional funding.
• The company is subject to risks associated with the development and commercialization of new technologies, including patent protection and market adoption.
• The company's business plan relies on securing project financing for its commercial ethanol to SAF facility, which is not guaranteed.

Future Outlook

The company anticipates needing additional funds for G&A expenses and will seek project financing for a commercial ethanol to SAF facility, in addition to funds needed to complete the commercialization of its CTS system. There is no guarantee that the company will achieve all of the additional funding that is needed.

Management Comments

• Management believes that the Company's future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing.
• Management believes that its management and consultants have significant experience in the development of technologies from concept to commercialization.

Industry Context

StockSavvy.ai notes that Blue Biofuels operates in the nascent but growing renewable energy and biofuels sector, specifically focusing on advanced technologies like CTS for converting cellulosic material into sugars and subsequently biofuels. The company's strategy to partner with Vertimass for Sustainable Aviation Fuel (SAF) production aligns with increasing industry demand for cleaner aviation alternatives and government incentives for renewable fuels.

Comparison to Industry Standards

• The company's reported net loss of $663,801 for the quarter, with no revenue, is typical for early-stage technology companies in the advanced biofuels sector that require significant R&D investment and capital for commercialization.
• Competitors in the advanced biofuels space, such as LanzaTech and Gevo, are also focused on developing and scaling up similar conversion technologies, often requiring substantial capital raises and strategic partnerships to achieve commercial viability.
• The company's reliance on government grants, like the SBIR grant from the DOE, is a common funding mechanism for innovative clean energy technologies, mirroring strategies employed by other companies in the sector seeking to de-risk early-stage development.

Legal Proceedings

• The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business.
• As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company's financial statements.

Related Party Transactions

• Notes payable to board member Chris Kneppers totaling $1,345,000 as of March 31, 2026, with repayment contingent on uplisting, significant equity financing, or revenue generation.
• Convertible notes with board member Edmund Burke totaling $190,000, with repayment contingent on equity investment, and issuance of warrants in lieu of interest.
• Deferred wages and directors fees related to CEO Ben Slager and CFO Anthony Santelli, with performance bonuses contingent on plant financing or uplisting.
• Restricted stock units and options granted to CEO Ben Slager, CFO Anthony Santelli, and Director Chris Kneppers as anti-dilution compensation for deferring salary or lending funds.
• A $500,000 bonus for CEO Ben Slager for meeting a milestone related to the CTS system, accrued in Deferred Wages and Directors Fees.

Stakeholder Impact

• Shareholders face continued dilution risk due to ongoing capital raises and potential for further stock issuances.
• The company's ability to continue as a going concern directly impacts all stakeholders, with significant doubt cast on its long-term viability without additional funding.
• Employees and directors may experience delayed or contingent compensation due to salary deferrals and performance-based bonuses tied to future financing or operational milestones.
• Creditors and noteholders face uncertainty regarding repayment, as many debt obligations are contingent on future events like uplisting or significant financing.

Next Steps

• Finalize design and operational parameters for cost estimates of a full-scale commercial volume system.
• Build commercial CTS and ethanol facilities on the front-end of ethanol-to-SAF facilities.
• Seek project financing for a commercial ethanol to SAF facility.
• Continue to seek additional financing for current and future operations.

Key Dates

Recommendation

While the company is making progress in technology development and securing some financing, the significant increase in net loss, dwindling cash reserves, and persistent going concern issues warrant a cautious approach. The potential for future capital raises and the successful commercialization of its technology are key factors, but the current financial performance and outlook suggest a 'hold' recommendation until more concrete revenue generation and improved financial stability are demonstrated.

Keywords

Blue Biofuels, 10-Q, Quarterly Report, Renewable Energy, Biofuels, Lignin, CTS Technology, Sustainable Aviation Fuel, SAF, Vertimass, VertiBlue Fuels, Financial Statements, SEC Filing, Going Concern, Stockholders Deficit, Research and Development